Coronavirus Notebook: EU In More Vaccine Talks, HTA Rolling Reviews, and RECOVERY’s UK Expansion

The European Commission is in talks to buy vaccines from CureVac and Moderna, amid concerns over “vaccine nationalism” and lack of transparency. Meanwhile the EU health technology assessment network has begun publishing “rolling collaborative reviews” of potential COVID-19 therapies, and two more firms have announced progress with monoclonal antibodies. 

COVID-19 vaccine ampules
Talks on purchasing COVID-19 vaccines are accelerating in the EU • Source: Shutterstock

EU efforts to secure a diversified portfolio of COVID-19 vaccines have taken another step forward after the European Commission confirmed it had completed exploratory talks with two more companies, CureVac BV and Moderna, Inc., for the purchase of potential vaccines against the SARS-CoV-2 virus. This brings to five the number of companies in vaccine talks with the EU.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

Making EU Clinical Trials Regulation A Success ‘Takes All Of Us To Tango’

 

Sponsors and regulatory agencies within the 27 EU member states must all be “committed” to working with the EU Clinical Trials Regulation in the most appropriate way to keep pace with other countries, including the UK where competition is heating up, says Miguel Forte, CEO of Kiji Therapeutics.

EU Biosimilar Filings, Opinions And Approvals

 

A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.

Industry Highlights Issues With EU HTA Regulation’s PICO Framework For Vaccines

 

Vaccine developers should be aware that the framework underpinning the new EU Health Technology Assessment (HTA) Regulation might not be suitable for immunizations, but actions from policymakers and industry could help mitigate some issues, a senior figure from GSK says.

EU HTA Regulation: Don’t Forget About Vaccines, Industry Warns

 

Europe’s vaccines industry wants to make sure immunizations “are not forgotten” by policymakers who are overseeing the EU Health Technology Assessment Regulation. It has highlighted several nuances of vaccines that should be addressed over the coming years.

More from Geography

Making EU Clinical Trials Regulation A Success ‘Takes All Of Us To Tango’

 

Sponsors and regulatory agencies within the 27 EU member states must all be “committed” to working with the EU Clinical Trials Regulation in the most appropriate way to keep pace with other countries, including the UK where competition is heating up, says Miguel Forte, CEO of Kiji Therapeutics.

ICH Modernizes Stability Testing Guideline

 
• By 

The International Council for Harmonisation has consolidated and modernized its existing stability guidelines into one document, and addressed modern stability testing approaches like modeling, bracketing, and matrixing.

EU Biosimilar Filings, Opinions And Approvals

 

A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.